Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

Published:2015-07-14 Issue:10 Volume:17 Page:936-948
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Rosenstock J.¹,Jelaska A.²,Zeller C.³,Kim G.⁴,Broedl U. C.⁴,Woerle H. J.⁴,

Affiliation:

1. Dallas Diabetes and Endocrine Center at Medical City Dallas TX USA

2. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA

3. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

4. Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany

Funder

Boehringer Ingelheim

Eli Lilly and Company

Pfizer

Roche

Bristol-Myers Squibb

AstraZeneca

Johnson and Johnson

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12503

Reference39 articles.

1. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes

3. Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes

4. The Treat-to-Target Trial

5. Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

3. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials;Journal of Cardiovascular Electrophysiology;2024-06-28

4. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

5. The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review;Journal of Mind and Medical Sciences;2024-04-30